Bioidentical hormones have been nominated to the FDA’s Difficult to Compound List, and items on this list when it is completed will no longer be able to be made at compounding pharmacies. Several bioidentical hormones (estriol, estradiol, progesterone, and testosterone) have been nominated to the list.
The FDA went after estriol in 2008, and the natural health community rose up to defend it—and we were successful! Now we need to send a strong message once again to defend consumer access to compounded bioidentical hormone replacement therapy.
Fill out the form below to send the message below to your Representative, Senators and the FDA.